Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients

Standard

Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients. / Hantke, Bernd; Harbeck, Nadia; Schmalfeldt, Barbara; Claes, Ingeborg; Hiller, Oliver; Luther, Marc-Oliver; Welk, Anita; Kuhn, Walther; Schmitt, Manfred; Tschesche, Harald; Muehlenweg, Bernd.

in: BIOL CHEM, Jahrgang 384, Nr. 8, 08.2003, S. 1247-51.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Hantke, B, Harbeck, N, Schmalfeldt, B, Claes, I, Hiller, O, Luther, M-O, Welk, A, Kuhn, W, Schmitt, M, Tschesche, H & Muehlenweg, B 2003, 'Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients', BIOL CHEM, Jg. 384, Nr. 8, S. 1247-51. https://doi.org/10.1515/BC.2003.137

APA

Hantke, B., Harbeck, N., Schmalfeldt, B., Claes, I., Hiller, O., Luther, M-O., Welk, A., Kuhn, W., Schmitt, M., Tschesche, H., & Muehlenweg, B. (2003). Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients. BIOL CHEM, 384(8), 1247-51. https://doi.org/10.1515/BC.2003.137

Vancouver

Bibtex

@article{ed82b81e28b04314b733668652587047,
title = "Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients",
abstract = "Matrix metalloproteinases (MMPs) are involved in many physiological and pathophysiological processes, including tumor cell invasion and metastasis. For one member of this family, MMP-13 (collagenase-3), a new, highly specific ELISA with a sensitivity of 0.5 ng MMP-13/ml was established. The protein levels of MMP-13 in ascitic fluids of 30 patients with advanced ovarian cancer FIGO stage III (n = 19) and IV (n = 11) were measured with this ELISA. Using a cut-off value of 0.5 ng MMP-13/mg total protein, two patient subpopulations with short (median 16 months) and long (median 36 months) overall survival were identified. Together with other prognostic markers, determination of MMP-13 in ascitic fluid may help to identify patients at risk for early death and help to individualize adjuvant therapy.",
keywords = "Adult, Aged, Aged, 80 and over, Animals, Antibodies, Monoclonal, Ascitic Fluid, Cell Line, Cell Line, Tumor, Collagenases, Enzyme-Linked Immunosorbent Assay, Female, Humans, Matrix Metalloproteinase 13, Mice, Mice, Inbred BALB C, Microscopy, Confocal, Middle Aged, Ovarian Neoplasms, Sensitivity and Specificity, Survival Rate",
author = "Bernd Hantke and Nadia Harbeck and Barbara Schmalfeldt and Ingeborg Claes and Oliver Hiller and Marc-Oliver Luther and Anita Welk and Walther Kuhn and Manfred Schmitt and Harald Tschesche and Bernd Muehlenweg",
year = "2003",
month = aug,
doi = "10.1515/BC.2003.137",
language = "English",
volume = "384",
pages = "1247--51",
journal = "BIOL CHEM",
issn = "1431-6730",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "8",

}

RIS

TY - JOUR

T1 - Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients

AU - Hantke, Bernd

AU - Harbeck, Nadia

AU - Schmalfeldt, Barbara

AU - Claes, Ingeborg

AU - Hiller, Oliver

AU - Luther, Marc-Oliver

AU - Welk, Anita

AU - Kuhn, Walther

AU - Schmitt, Manfred

AU - Tschesche, Harald

AU - Muehlenweg, Bernd

PY - 2003/8

Y1 - 2003/8

N2 - Matrix metalloproteinases (MMPs) are involved in many physiological and pathophysiological processes, including tumor cell invasion and metastasis. For one member of this family, MMP-13 (collagenase-3), a new, highly specific ELISA with a sensitivity of 0.5 ng MMP-13/ml was established. The protein levels of MMP-13 in ascitic fluids of 30 patients with advanced ovarian cancer FIGO stage III (n = 19) and IV (n = 11) were measured with this ELISA. Using a cut-off value of 0.5 ng MMP-13/mg total protein, two patient subpopulations with short (median 16 months) and long (median 36 months) overall survival were identified. Together with other prognostic markers, determination of MMP-13 in ascitic fluid may help to identify patients at risk for early death and help to individualize adjuvant therapy.

AB - Matrix metalloproteinases (MMPs) are involved in many physiological and pathophysiological processes, including tumor cell invasion and metastasis. For one member of this family, MMP-13 (collagenase-3), a new, highly specific ELISA with a sensitivity of 0.5 ng MMP-13/ml was established. The protein levels of MMP-13 in ascitic fluids of 30 patients with advanced ovarian cancer FIGO stage III (n = 19) and IV (n = 11) were measured with this ELISA. Using a cut-off value of 0.5 ng MMP-13/mg total protein, two patient subpopulations with short (median 16 months) and long (median 36 months) overall survival were identified. Together with other prognostic markers, determination of MMP-13 in ascitic fluid may help to identify patients at risk for early death and help to individualize adjuvant therapy.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Animals

KW - Antibodies, Monoclonal

KW - Ascitic Fluid

KW - Cell Line

KW - Cell Line, Tumor

KW - Collagenases

KW - Enzyme-Linked Immunosorbent Assay

KW - Female

KW - Humans

KW - Matrix Metalloproteinase 13

KW - Mice

KW - Mice, Inbred BALB C

KW - Microscopy, Confocal

KW - Middle Aged

KW - Ovarian Neoplasms

KW - Sensitivity and Specificity

KW - Survival Rate

U2 - 10.1515/BC.2003.137

DO - 10.1515/BC.2003.137

M3 - SCORING: Journal article

C2 - 12974393

VL - 384

SP - 1247

EP - 1251

JO - BIOL CHEM

JF - BIOL CHEM

SN - 1431-6730

IS - 8

ER -